Common Pathogenic Mechanisms between Down Syndrome and Alzheimer's Disease: Steps toward Therapy

Book Series: Recent Advances in Alzheimer Research

Volume 1

by

Ahmad Salehi, Michael Rafii, Cristy Phillips

DOI: 10.2174/97816810813801150101
eISBN: 978-1-68108-138-0, 2015
ISBN: 978-1-68108-139-7
ISSN: 2452-2554 (Print)
ISSN: 2452-2562 (Online)



Indexed in: EBSCO.

Down syndrome is a chromosomal disorder affecting more than 5.8 million individuals worldwide. Down syndrome can be viewed as a comple...[view complete introduction]
US $
Buy Personal eBook
129
Order Library eBook
516
Order Printed Copy
*155
Order PDF + Printed Copy (Special Offer)
*219

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology

Overview of Recent Clinical Trials for Cognitive Dysfunction in Alzheimer’s Disease and Down Syndrome

- Pp. 292-300 (9)

Michael S. Rafii

Abstract

Down syndrome (DS) is a genetic disorder that results from the triplication of chromosome 21. Accompanying this disorder are a number of medical conditions including intellectual disability and early- onset Alzheimer’s disease (AD). Our understanding of the molecular basis for these has expanded substantially in the past decade, both in patients and relevant animal models. In particular, exciting advances in therapies that modulate neurotransmitters to improve cognitive function have reached clinical trials. Moreover, increased insight into the pathogenesis of AD in DS has motivated clinical trials for AD in DS. Below, therapeutic strategies that have been deployed in clinical trials in DS will be discussed as well as their underlying scientific rational.

Purchase Chapter  Book Details

Advertisement


Webmaster Contact: info@benthamscience.org Copyright © 2018 Bentham Science